Novavax (MEX:NVAX) Accounts Payable: MXN290 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NVAX Novavax Inc MEX:NVAX
42 GF Score
Price MXN132.00
GF Value MXN64.32
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novavax Accounts Payable?

Novavax MEX:NVAX +3.03% 42 Accounts Payable is MXN290 Mil as of Mar. 2026. GuruFocus rates MEX:NVAX with a GF Score™ of 42/100 and a GF Value™ of MXN64.32 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Novavax's Accounts Payable for the quarter that ended in Mar. 2026 was MXN290 Mil.

Novavax's quarterly Accounts Payable increased from Sep. 2025 (MXN279 Mil) to Dec. 2025 (MXN443 Mil) but then declined from Dec. 2025 (MXN443 Mil) to Mar. 2026 (MXN290 Mil).

Novavax's annual Accounts Payable declined from Dec. 2023 (MXN2,251 Mil) to Dec. 2024 (MXN867 Mil) and declined from Dec. 2024 (MXN867 Mil) to Dec. 2025 (MXN443 Mil).

Novavax Accounts Payable Historical Data

* Premium members only.

The historical data trend for Novavax's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Accounts Payable Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,606.30 4,221.22 2,250.96 867.16 442.54

Novavax Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 698.89 952.66 279.33 442.54 290.35
MEX:NVAX
42GF Score
Novavax Inc MEX:NVAX
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of MXN290 Mil mean?
Novavax (MEX:NVAX) has a Accounts Payable of MXN290 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Novavax and its competitors.
Is Novavax's Accounts Payable too high?
Novavax's current Accounts Payable is MXN290 Mil. Overall, Novavax has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Accounts Payable compare to JBIO and AVLN?
Novavax's Accounts Payable of MXN290 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Novavax and its competitors. Novavax's current Accounts Payable is MXN290 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (MEX:NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN64.32, compared to a current price of MXN132.00 — trading 105.2% above its estimated fair value. The current Accounts Payable is MXN290 Mil. Novavax's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Novavax (MEX:NVAX), the current Accounts Payable is MXN290 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (MEX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of MXN132.00 is trading 105.2% above its estimated GF Value™ of MXN64.32. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for MEX:NVAX:

  • Accounts Payable: MXN290 Mil
  • GF Value™: MXN64.32 vs. price of MXN132.00 (105.2% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the MEX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
42GF Score

Get the complete analysis for MEX:NVAX

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN132.00
Price
MXN64.32
GF Value